Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function - Long, S. Alice; Rieck, Mary; Sanda, Srinath; Bollyky, Jennifer B.; Samuels, Peter L.; Goland, Robin; Ahmann, Andrew; Rabinovitch, Alex; Aggarwal, Sudeepta; Phippard, Deborah; Turka, Laurence A.; Ehlers, Mario R.; et al. (Diabetes (New York, N.Y.), 2012)
Keywords: Animals; Biological and medical sciences; Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 1 - immunology; Diabetes. Impaired glucose tolerance; Dosage and administration; Drug therapy; Drug Therapy, Combination; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Humans; Immunology and Transplantation; Insulin-Secreting Cells - drug effects; Insulin-Secreting Cells - physiology; Interleukin-2; Interleukin-2 - administration & dosage; Interleukin-2 - therapeutic use; Medical sciences; Mice; Mice, Inbred NOD; Rapamycin; Sirolimus; Sirolimus - administration & dosage; T-Lymphocytes, Regulatory - immunology; Type 1 diabetes; Endocrinopathy; Human; Immunopathology; Interleukin 2; Type 1 diabetes; Cytokine; Langerhans islet; Autoimmune disease; β Cell; Endocrine pancreas